Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

New Cannabinoid Treatment for Pets on the Horizon?

Splash Beverage Group has announced an exciting expansion of its CannEpil® platform into veterinary medicine, allowing the company to develop treatments for companion animals. This proprietary formulation, which combines cannabidiol (CBD) and tetrahydrocannabinol (THC), was initially created to help manage drug-resistant epilepsy in humans. Now, Splash aims to address significant health issues in pets, focusing on oncology and chronic pain management, particularly in dogs. This move taps into a booming market, with veterinary pain management projected to grow from $2.6 billion in 2024 to $3.8 billion by 2030, driven by increasing pet ownership and demand for advanced care.

For pet owners concerned about their furry friends’ health, this development could lead to new treatment options for conditions like cancer and chronic pain. With one in four dogs expected to develop cancer during their lifetime, and half of dogs over ten facing similar diagnoses, the potential impact of CannEpil is significant. By targeting these pressing health issues, Splash’s initiative could improve the quality of life for countless pets and provide their owners with more effective treatment options.

Currently, the research is in its early stages, as Splash plans to navigate the FDA’s regulatory pathways for veterinary use. The company has been granted an Investigational New Animal Drug (INAD) application number and aims to pursue conditional approval through established veterinary channels. While the potential for CannEpil in veterinary medicine is promising, it remains to be seen how successful the development and approval processes will be.

As this initiative unfolds, pet owners should stay informed about advancements in veterinary cannabinoid therapies, as they may soon have access to innovative treatments that could enhance their pets’ well-being.

Original source